Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion

References

• Cai Q, Luo X, Zhang G, et al. New prognostic model for extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2014;93:1541–1549.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang H, Wang J, et al. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015;6:30317–30326.
   PubMed Web of Science ®Google Scholar
• William BM, Armitage JO. International analysis of the frequency and outcomes of NK/T-cell lymphomas. Best Pract Res Clin Haematol. 2013;26:23–32.
   PubMed Web of Science ®Google Scholar
• Au W, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-cell lymphoma project. Blood. 2009;113:3931–3937.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhu F, Liu X, et al. Radiotherapy combined with chemotherapy versus radiotherapy alone for early stage nasal natural killer/T-cell lymphoma: a meta-analysis. J Chemother. 2016;28:65–71.
   PubMedGoogle Scholar
• Yamaguchi M, Kwong Y-L, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal Natural Killer (NK)/T-cell lymphoma, nasal type: the NK-cell tumor study group study. J Clin Oncol. 2011;29:4410–4416.
   PubMed Web of Science ®Google Scholar
• Kwong Y-L, Kim WS, Lim ST, et al. SMILE for natural killer (NK)/T-cell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group. Blood. 2012. blood-2012-05-431460.
   Google Scholar
• Yang L, Liu H, Xu X, et al. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Med Oncol. 2013;30:720.
   PubMed Web of Science ®Google Scholar
• Lee SH, Ahn YC, Kim WS, et al. The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma. Haematologica. 2006;91:427–428.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009;27:6027–6032.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Oguchi M, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol. 2016;35:32–39.
   PubMed Web of Science ®Google Scholar
• Pokrovsky VS, Vinnikov D. L-asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis. Expert Rev Anticancer Ther. 2017;17:759–768.
   PubMed Web of Science ®Google Scholar
• Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin Cancer Res. 2016. clincanres.0153.2016;22(21):5223-5228.
   Web of Science ®Google Scholar
• Wang H, Wuxiao Z, Zhu J, et al. The comparison of GELOX (gemcitabine, oxaliplatin, and L-asparaginase) and EPOCH as first-line chemotherapy in patients with stage IE to II E extranodal natural killer/T-cell lymphoma: a multi-center retrospective study. Leuk Lymphoma. 2015;56:971–977.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–341.
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhu J, et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol. 2006;24:28–32.
   PubMed Web of Science ®Google Scholar
• Wang H, Wuxiao Z-J, Zhu J, et al. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study. Leuk Lymphoma. 2015;56:971–977.
   PubMed Web of Science ®Google Scholar
• Cao J, Lan S, Shen L, et al. A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: the efficacy of CHOP regimen based concurrent chemoradiotherapy. Oncotarget. 2016;8:20362–20370.
   Google Scholar
• Huang L, Yuan B, Wu H, et al. Comparative study of L-asparaginase-based LOP regimen over CHOP regimen before radiotherapy for stage IIE Extranodal Nasal Type NK/T cell lymphoma: a study of 2 centers. Clin Lymphoma Myeloma Leuk. 2017;17:152–158.
   PubMed Web of Science ®Google Scholar
• Guo H-Q, Liu L, Wang X-F, et al. Efficacy of gemcitabine combined with oxaliplatin, L‑asparaginase and dexamethasone in patients with newly‑diagnosed extranodal NK/T‑cell lymphoma. Mol. Clin. Oncol. 2014;2:1172–1176.
   PubMedGoogle Scholar
• Li J-W, Li Y-J, Zhong M-Z, et al. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study. Eur J Haematol. 2018;100:247–256.
   PubMed Web of Science ®Google Scholar
• Kim M, Kim TM, Kim KH, et al. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus l-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). Ann Hematol. 2015;94:437–444.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Park S, Kang ES, et al. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. Ann Hematol. 2015;94:71–78.
   PubMed Web of Science ®Google Scholar
• Wei W, Wu P, Li L, et al. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. Hematology. 2016;22(6):1–10.
   Web of Science ®Google Scholar
• Huang Y, Yang J, Liu P, et al. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2017;96:1477–1483.
   PubMed Web of Science ®Google Scholar
• Jiang M, Zhang L, Xie L, et al. A phase II prospective study of the “Sandwich” protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. Oncotarget. 2017;8:50155–50163.
   PubMedGoogle Scholar
• Arora N, Mehta A, Ravichandran S, et al. NK/T cell lymphoma: a tertiary centre experience. Indian J Hematol Blood Transfus. 2017;33(1):69-73.
   Web of Science ®Google Scholar
• Yoon DH, Kim SJ, Jeong SH, et al. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget. 2016;7:85584–85591.
   PubMed Web of Science ®Google Scholar
• Ji J, Liu T, Xiang B, et al. A study of gemcitabine, L-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type. Leuk Lymphoma. 2014;55:2955–2957.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Kang HJ, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012;48:3223–3231.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang H, Wang Y, et al. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma. Oncotarget. 2016;7:35412.
   PubMedGoogle Scholar
• Zhang L, Li S, Jia S, et al. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type. Oncotarget. 2016;7:58396–58404.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li X, Chen C, et al. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Ann Hematol. 2014;93:1889–1894.
   PubMed Web of Science ®Google Scholar
• Lin N, Song Y, Zheng W, et al. A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. J Hematol Oncol. 2013;6:44.
   PubMed Web of Science ®Google Scholar
• Jiang M, Zhang H, Jiang Y, et al. Phase 2 trial of “Sandwich” L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer. 2012;118:3294–3301.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117:1834–1839.
   PubMed Web of Science ®Google Scholar
• Raja RA, Schmiegelow K, Frandsen TL. Asparaginase‐associated pancreatitis in children. Br J Haematol. 2012;159:18–27.
   PubMed Web of Science ®Google Scholar
• Bi X, Xia Y, Zhang W, et al. Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Ann Hematol. 2015;94:1525–1533.
   PubMed Web of Science ®Google Scholar
• Bu S, Yuan F, Wei X, et al. L‑asparaginase‑based regimen as a first‑line treatment for newly diagnosed nasal type extranodal natural killer cell/T‑cell lymphoma. Exp Ther Med. 2016;11:2437–2445.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Z, Chen X, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119:348–355.
   PubMed Web of Science ®Google Scholar
• Dong L-H, Zhang L-J, Wang W-J, et al. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma. Leuk Lymphoma. 2016;57:1600–1606.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27:5594–5600.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010;115:1351–1353.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children’s cancer group study. Blood. 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Wang YQ, Yang Y, Zhuo HY, et al. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma. Med Oncol. 2015;32:9.
   Web of Science ®Google Scholar
• Zhou F, Xue H, Zhao Y, et al. A prospective study of chemoradiotherapy for early stage extranodal natural killer (NK)/T-cell lymphoma. Int J Clin Exp Med. 2016;9:14397–14403.
   Web of Science ®Google Scholar
• Huang H, Lin Z, Lin X, et al. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience. Leuk Lymphoma. 2011;52:1041–1048.
   PubMed Web of Science ®Google Scholar
• Kim TM, Kim D-W, Kang Y-K, et al. A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the korean cancer study group. Oncologist. 2014;19:1129–1130.
   PubMed Web of Science ®Google Scholar
• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52:2237–2253.
   PubMed Web of Science ®Google Scholar
• Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on dana‐farber cancer institute consortium protocols. Br J Haematol. 2011;152:452–459.
   PubMed Web of Science ®Google Scholar
• Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia. 2013;27:553–559.
   PubMed Web of Science ®Google Scholar
• Liang R, Gao G, Chen J, et al. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T‐cell lymphoma, nasal type: a multicenter trial in Northwest China. Hematol Oncol. 2017;35(4):619-629.
   Web of Science ®Google Scholar
• Ding H, Chang J, L-G L, et al. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study. Int J Hematol. 2015;102:181–187.
   PubMed Web of Science ®Google Scholar
• Sannikova EP, Bulushova NV, Cheperegin SE, et al. The modified heparin-binding l-asparaginase of wolinella succinogenes. Mol Biotechnol. 2016;58:528–539.
   PubMed Web of Science ®Google Scholar
• Sidoruk KV, Pokrovsky VS, Borisova AA, et al. Creation of a producent, optimization of expression, and purification of recombinant Yersinia pseudotuberculosis L-asparaginase. Bull Exp Biol Med. 2011;152:219–223.
   PubMed Web of Science ®Google Scholar
• Pokrovskaya MV, Aleksandrova SS, Pokrovsky VS, et al. Cloning, expression and characterization of the recombinant Yersinia pseudotuberculosisl-asparaginase. Protein Expr Purif. 2012;82:150–154.
   PubMed Web of Science ®Google Scholar
• Pokrovskaya MV, Aleksandrova SS, Pokrovsky VS, et al. Identification of Functional Regions in the rhodospirillum rubrum L-asparaginase by site-directed mutagenesis. Mol Biotechnol. 2015;57:251–264.
   PubMed Web of Science ®Google Scholar
• Pokrovsky VS, Kazanov MD, Dyakov IN, et al. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases. BMC Cancer. 2016;16:89.
   PubMed Web of Science ®Google Scholar
• Melik-Nubarov NS, Grozdova ID, Lomakina GY, et al. PEGylated recombinant L-asparaginase from Erwinia carotovora: production, properties, and potential applications. Appl Biochem Microbiol. 2017;53:165–172.
   Web of Science ®Google Scholar
• Yao Y, Tang Y, Zhuang Y, et al. Retrospective study of pegaspargase, gemicitabine, oxaliplatin and dexamethasone (Peg-GemOD) as a first-line therapy for advanced-stage extranodal NK/T cell lymphoma. Indian J Hematol Blood Transfus. 2017;33(1):74-81.
   Web of Science ®Google Scholar
• Kim SJ, Yang D-H, Kim JS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014;93:1895–1901.
   PubMed Web of Science ®Google Scholar
• Oh D, Ahn YC, Kim SJ, et al. Concurrent chemoradiation therapy followed by consolidation chemotherapy for localized extranodal natural killer/T-cell lymphoma, nasal type. Int J Radiat Oncol. 2015;93:677–683.
   PubMed Web of Science ®Google Scholar
• Huang M, Jiang Y, Liu W, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008;70:166–174.
   PubMed Web of Science ®Google Scholar
• Kim SM, Park S, Oh DR, et al. Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability. Ann Hematol. 2016;95:581–591.
   PubMed Web of Science ®Google Scholar
• Li X, Cheng Y, Zhang M, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018;11:15.
   PubMed Web of Science ®Google Scholar
• Hari P, Raj RV, Olteanu H. Targeting CD38 in refractory extranodal natural killer Cell–T-cell lymphoma. N Engl J Med. 2016;375:1501–1502.
   PubMed Web of Science ®Google Scholar
• Kim HK, Moon SM, Moon JH, et al. Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. Blood Res. 2015;50:254–256.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Z-H, Chen X-Q, et al. First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: an updated analysis with long-term follow-up. Oncol Lett. 2015;10:1036–1040.
   PubMed Web of Science ®Google Scholar
• Lo Bello G, Akarca AU, Ambrosio MR, et al. Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. Virchows Arch. 2018. DOI:10.1007/s00428-018-2434-x.
   PubMed Web of Science ®Google Scholar
• Miyata-Takata T, Chuang SS, Takata K, et al. Expression of T-cell receptor signalling pathway components in extranodal NK/T-cell lymphoma. Histopathology. 2018. DOI:10.1111/his.13728.
   PubMed Web of Science ®Google Scholar